Skip to Content
Merck
All Photos(2)

Documents

SRP6155

Sigma-Aldrich

BMP-2 human

recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE)

Synonym(s):

BMP-2A, Bone morphogenetic protein 2, Bone morphogenetic protein 2A

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352202
NACRES:
NA.32

biological source

human

recombinant

expressed in HEK 293 cells

Assay

≥95% (SDS-PAGE)

form

lyophilized

potency

20-100 ng/mL ED50

mol wt

30-38 kDa (homodimer, glycosylated)

packaging

pkg of 10 μg

technique(s)

cell culture | mammalian: suitable

NCBI accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... BMP2(650)

General description

BMP2 (bone morphogenetic protein 2) belongs to the transforming growth factor-β (TGFβ) superfamily. BMP-2 is expressed in a variety of tissues such as lung, spleen, brain, liver, prostate ovary, and small intestine. BioVision′s BMP-2 is produced in a serum-free, chemically defined media. Production in human 293 cells offers authentic glycosylation, contributing to stability in cell growth media and other applications.BMP2 is a candidate gene for the autosomal dominant disease of fibrodysplasia (myositis) ossificans progressiva.

Application

BMP-2 human has been used to study the biological role of it on adult renal progenitor cells under in vitro and in vivo conditions.

Biochem/physiol Actions

BMPs (bone morphogenetic proteins) promote and regulate bone development, growth, remodeling and repair, in both prenatal development and postnatal growth of eye, heart, kidney, skin, and other tissues. During bone repair, BMP-2 controls the expression of Runt-related transcription factor 2 (Runx2) and Osterix (Osx), thereby enhancing migration, proliferation and osteogenic differentiation of mesenchymal stem cells. In addition to its osteogenic activity, BMP-2 also plays an important role in cardiac morphogenesis.

Physical form

Lyophilized from a solution of 50 mM sodium acetate, pH 4.5, with 50 mM NaCl.

Preparation Note

Centrifuge the vial prior to opening.

Reconstitution

Reconstitute in sterile PBS containing 0.1% endotoxin-free, recombinant human serum albumin.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

BMP-2 induces a profibrotic phenotype in adult renal progenitor cells through Nox4 activation.
Simone S, et al.
American Journal of Physiology: Renal Physiology, 303, F23-F34 (2012)
Vera Hintze et al.
Biomacromolecules, 15(8), 3083-3092 (2014-07-17)
Sulfated glycosaminoglycans (GAGs) can direct cellular processes by interacting with proteins of the extracellular matrix (ECM). In this study we characterize the interaction profiles of chemically sulfated hyaluronan (HA) and chondroitin sulfate (CS) derivatives with bone morphogenetic protein-2 (BMP-2) and
Rick Visser et al.
Tissue engineering. Part A, 20(1-2), 34-44 (2013-07-19)
Osteogenesis is a complex, multifactorial process in which many different signals interact. The bone morphogenetic proteins (BMPs) are the most potent inducers of osteoblastic differentiation, although very high doses of BMPs in combination with collagen type I formulations have to
Ivo Dumic-Cule et al.
International orthopaedics, 38(9), 1979-1985 (2014-07-18)
Bone morphogenetic protein (BMP)-2 and -7 are used in patients with long-bone fractures, nonunions and spinal fusions. It is unknown whether their potential systemic bioavailability following local bone administration might affect skeletal metabolism. To answer this question, we examined effects
Nam Hee Kim et al.
Biomaterials, 35(37), 9888-9896 (2014-09-15)
Though growth factors allow tissue regeneration, the trade-off between their effectiveness and adverse effects limits clinical application. The key issues in current growth factor therapy largely derive from initial burst pharmacokinetics, rapid clearance, and proteolytic cleavage resulting in clinical ineffectiveness

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service